plerixafor and s 1033
plerixafor has been researched along with s 1033 in 4 studies
Research
Studies (4)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
Authors
| Authors | Studies |
|---|---|
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Calandra, G; Dillmann, F; Fruehauf, S; Laufs, S; Sperandio, M; Veldwijk, MR; Wenz, F; Zeller, J | 1 |
| Fava, C; Saglio, G | 1 |
| Azab, AK; Bronson, R; Christie, AL; Ghobrial, IM; Griffin, JD; Kung, AL; Manley, PW; Weisberg, E | 1 |
Reviews
1 review(s) available for plerixafor and s 1033
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Other Studies
3 other study(ies) available for plerixafor and s 1033
| Article | Year |
|---|---|
Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib.
Topics: Animals; Benzamides; Benzylamines; Cell Adhesion; Cell Line; Cell Line, Tumor; Chemokine CXCL12; Coculture Techniques; Cyclams; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Heterocyclic Compounds; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Stromal Cells | 2009 |
Inhibition of stromal cell-derived factor-1/CXCR4 axis for the cure of BCR-ABL positive chronic myeloid leukemia.
Topics: Antiviral Agents; Benzamides; Benzylamines; Bone Marrow; Cell Adhesion; Cell Line, Tumor; Chemokine CXCL12; Cyclams; Drug Resistance, Neoplasm; Heterocyclic Compounds; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Proteins; Neoplastic Stem Cells; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Receptors, CXCR4; Secondary Prevention; Stromal Cells | 2009 |
Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.
Topics: Animals; Antineoplastic Agents; Benzylamines; Bone Marrow Cells; Cell Adhesion; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Cyclams; Drug Resistance, Neoplasm; Flow Cytometry; Heterocyclic Compounds; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Pyrimidines; Receptors, CXCR4; Stromal Cells | 2012 |